| 1 |
33961299 | Effects of 27 CYP3A4 protein variants on saxagliptin metabolism in vitro. | 2022 Feb |
2 |
| 2 |
34841901 | Targeting the NOD-Like Receptor Pyrin Domain Containing 3 Inflammasome to Improve Healing of Diabetic Wounds. | 2022 Jan 13 |
1 |
| 3 |
35388920 | New enantioselective liquid chromatography method development and validation of dipeptidyl peptidase IV inhibitors using a macrocyclic glycopeptide (vancomycin) chiral stationary phase under polar ionic mode condition. | 2022 Jul |
2 |
| 4 |
32741073 | Dipeptidyl peptidase-4 inhibitor treatment and the risk of bullous pemphigoid and skin-related adverse events: A systematic review and meta-analysis of randomized controlled trials. | 2021 Mar |
1 |
| 5 |
32809070 | Real-world adherence, persistence, and in-class switching during use of dipeptidyl peptidase-4 inhibitors: a systematic review and meta-analysis involving 594,138 patients with type 2 diabetes. | 2021 Jan |
1 |
| 6 |
33068301 | Saxagliptin and vildagliptin lowered albuminuria in patients with diabetes and hypertension independent on glycaemic control. | 2021 Mar |
1 |
| 7 |
34384428 | Impact on decision making framework for medicine purchasing in Chinese public hospital decision-making: determining the value of five dipeptidyl peptidase 4 (DPP-4) inhibitors. | 2021 Aug 12 |
1 |
| 8 |
34484112 | Cost-Effectiveness of Dipeptidylpeptidase-4 Inhibitors Added to Metformin in Patients With Type 2 Diabetes in China. | 2021 |
2 |
| 9 |
34737703 | Effect of CYP3A4 Inhibitors and Inducers on Pharmacokinetics and Pharmacodynamics of Saxagliptin and Active Metabolite M2 in Humans Using Physiological-Based Pharmacokinetic Combined DPP-4 Occupancy. | 2021 |
2 |
| 10 |
32043288 | Adding vitamin D3 to the dipeptidyl peptidase-4 inhibitor saxagliptin has the potential to protect β-cell function in LADA patients: A 1-year pilot study. | 2020 Jul |
1 |
| 11 |
32587614 | From Prediabetes to Type 2 Diabetes Mellitus in Women with Polycystic Ovary Syndrome: Lifestyle and Pharmacological Management. | 2020 |
1 |
| 12 |
32909376 | Non-insulin antihyperglycaemic drugs and heart failure: an overview of current evidence from randomized controlled trials. | 2020 Sep 10 |
1 |
| 13 |
32948146 | Protective effects of DPP-4 inhibitor on podocyte injury in glomerular diseases. | 2020 Sep 18 |
4 |
| 14 |
32990096 | Efficacy and safety of saxagliptin for the treatment of type 2 diabetes mellitus. | 2020 Dec |
1 |
| 15 |
33001278 | The DPP-IV inhibitor saxagliptin promotes the migration and invasion of papillary thyroid carcinoma cells via the NRF2/HO1 pathway. | 2020 Oct 1 |
2 |
| 16 |
33116702 | Effect of Saxagliptin, a Dipeptidyl Peptidase 4 Inhibitor, on Non-Alcoholic Fatty Liver Disease. | 2020 |
1 |
| 17 |
33163625 | LINAGLIPTIN-INDUCED PANCREATITIS. | 2020 Jan-Feb |
1 |
| 18 |
30500110 | Pharmacokinetic Interaction Study Between Saxagliptin and Omeprazole, Famotidine, or Magnesium and Aluminum Hydroxides Plus Simethicone in Healthy Subjects: An Open-Label Randomized Crossover Study. | 2019 May |
1 |
| 19 |
30639312 | The DPP-4 inhibitor saxagliptin ameliorates ox-LDL-induced endothelial dysfunction by regulating AP-1 and NF-κB. | 2019 May 15 |
1 |
| 20 |
30767126 | Cardiovascular Protection with Anti-hyperglycemic Agents. | 2019 Jun |
2 |
| 21 |
30942641 | The protective effects of saxagliptin against lipopolysaccharide (LPS)-induced inflammation and damage in human dental pulp cells. | 2019 Dec |
2 |
| 22 |
31018682 | Dipeptidyl peptidase-4 inhibitors and cardiovascular and renal disease in type 2 diabetes: What have we learned from the CARMELINA trial? | 2019 Jul |
1 |
| 23 |
31127397 | Assessment of Heart Failure in Diabetes Cardiovascular Outcomes Trials: Is What We Are Currently Capturing Adequate? | 2019 May 24 |
1 |
| 24 |
31164243 | DPP-4 Inhibitor Dose Selection According to Manufacturer Specifications: A Contemporary Experience From UK General Practice. | 2019 Aug |
2 |
| 25 |
31275243 | DPP-4 Inhibition and the Path to Clinical Proof. | 2019 |
1 |
| 26 |
31308448 | Effect of Saxagliptin on Endothelial Function in Patients with Type 2 Diabetes: A Prospective Multicenter Study. | 2019 Jul 15 |
1 |
| 27 |
31364869 | Saxagliptin suppresses degradation of type II collagen and aggrecan in primary human chondrocytes: a therapeutic implication in osteoarthritis. | 2019 Dec |
1 |
| 28 |
31737185 | DPP-4 inhibitor saxagliptin ameliorates oxygen deprivation/reoxygenation-induced brain endothelial injury. | 2019 |
3 |
| 29 |
31792328 | DPP8 is a novel therapeutic target for multiple myeloma. | 2019 Dec 2 |
1 |
| 30 |
29122893 | Prospective Postmarketing Surveillance of Acute Myocardial Infarction in New Users of Saxagliptin: A Population-Based Study. | 2018 Jan |
1 |
| 31 |
29270818 | The influence of anti-hyperglycemic drug therapy on cardiovascular and heart failure outcomes in patients with type 2 diabetes mellitus. | 2018 May |
2 |
| 32 |
29359260 | Clinical impact of oral antidiabetic medications in heart failure patients. | 2018 May |
1 |
| 33 |
29520964 | Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. | 2018 May |
1 |
| 34 |
29549573 | Pharmacovigilance Evaluation of the Association Between DPP-4 Inhibitors and Heart Failure: Stimulated Reporting and Moderation by Drug Interactions. | 2018 Apr |
2 |
| 35 |
29679391 | Cardiovascular effects of sitagliptin - An anti-diabetes medicine. | 2018 Jul |
1 |
| 36 |
29682682 | Molecular and clinical roles of incretin-based drugs in patients with heart failure. | 2018 May |
1 |
| 37 |
29724198 | The synergistic effects of saxagliptin and metformin on CD34+ endothelial progenitor cells in early type 2 diabetes patients: a randomized clinical trial. | 2018 May 3 |
1 |
| 38 |
29807374 | [Diabetes Mellitus Type 2: Recent Publications and New Drugs]. | 2018 Jun |
1 |
| 39 |
29912623 | Saxagliptin Upregulates Nesfatin-1 Secretion and Ameliorates Insulin Resistance and Metabolic Profiles in Type 2 Diabetes Mellitus. | 2018 Sep |
2 |
| 40 |
30249630 | Efficacy and tolerability of novel triple combination therapy in drug-naïve patients with type 2 diabetes from the TRIPLE-AXEL trial: protocol for an open-label randomised controlled trial. | 2018 Sep 24 |
1 |
| 41 |
30487758 | Saxagliptin but Not Sitagliptin Inhibits CaMKII and PKC via DPP9 Inhibition in Cardiomyocytes. | 2018 |
1 |
| 42 |
33693068 | Anti-Diabetic Agents and Heart Failure - Response to the CARMELINA Study. | 2018 Dec 11 |
1 |
| 43 |
27282159 | Clinical Pharmacokinetics and Pharmacodynamics of Saxagliptin, a Dipeptidyl Peptidase-4 Inhibitor. | 2017 Jan |
3 |
| 44 |
27653447 | Heart failure outcomes in clinical trials of glucose-lowering agents in patients with diabetes. | 2017 Jan |
1 |
| 45 |
28176222 | Saxagliptin/Dapagliflozin: A Review in Type 2 Diabetes Mellitus. | 2017 Mar |
1 |
| 46 |
28182722 | Hemoglobin glycation index as a useful predictor of therapeutic responses to dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes. | 2017 |
1 |
| 47 |
28228317 | Short-term therapy with combination dipeptidyl peptidase-4 inhibitor saxagliptin/metformin extended release (XR) is superior to saxagliptin or metformin XR monotherapy in prediabetic women with polycystic ovary syndrome: a single-blind, randomized, pilot study. | 2017 Jan |
1 |
| 48 |
28367418 | Micro-Environmental Signature of The Interactions between Druggable Target Protein, Dipeptidyl Peptidase-IV, and Anti-Diabetic Drugs. | 2017 Apr-Jun |
2 |
| 49 |
28407661 | Effect of Saxagliptin on Circulating Endothelial Progenitor Cells and Endothelial Function in Newly Diagnosed Type 2 Diabetic Patients. | 2017 Jun |
1 |
| 50 |
28417296 | DPP4 inhibitors and cardiovascular outcomes: safety on heart failure. | 2017 May |
1 |